The Pharmacy Times® Rheumatoid Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
FDA Approves Golimumab for Active Polyarticular Juvenile Idiopathic Arthritis, Extension of PsA Indication
The FDA has approved golimumab for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.
Inflammation caused by rheumatoid arthritis may increase the risk of type 2 diabetes.
The FDA has approved tofacitinib for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis.
A recent study found that patients on immunosuppressive therapy for common skin and rheumatic diseases, such as psoriasis and rheumatoid arthritis, are not at an increased risk for contracting COVID-19.
Recent studies have analyzed how individuals with autoimmune conditions prescribed specialty medications may be affected by the COVID-19 pandemic.
The Mediterranean diet has shown efficacy in preventing several noncommunicable diseases.
Research Shows Adults With Lupus, Common Types of Arthritis Have Similar Risks of Being Hospitalized as Other Patients With COVID-19
The new studies found that for some patients, the use of steroid medications to reduce inflammation slighly increased the likelihood of needing hospital care for COVID-19.
Extended glucocorticoid use can cause complications such as cardiovascular disorders, infections, and osteoporosis, according to a new study.
What characteristics of RA treatments possibly connect to COVID-19 treatment?
The American College of Rheumatology addresses the prior authorization requirement for some prescription medications, highlighting the significant burden this creates for patients and rheumatology professionals.
The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.
Officials with the FDA have approved Amgen’s infliximab-axxq (Avsola), a new biosimiliar to infliximab (Remicade).